Enanta Pharmaceuticals, Inc (ENTA)

Etorro trading 970x250
Enanta Pharmaceuticals, Inc (ENTA) Logo

About Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472

Enanta Pharmaceuticals, Inc News and around…

Latest news about Enanta Pharmaceuticals, Inc (ENTA) common stock and company :

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
19 May, 2022 Yahoo! Finance

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Enanta's stock is down after its experimental RSV treatment failed in a mid-stage clinical trial
19 May, 2022 Yahoo! Finance

Shares of Enanta Pharmaceuticals Inc. slid 19.3% in premarket trading on Thursday, the day after the company said its experimental treatment for respiratory syncytial virus did not meet the primary endpoint in a Phase 2b clinical trial. The therapy did not reduce symptoms when compared to placebo; however, the company said there was a statistically significant difference in the number of adult patients that reported undetectable RNA at day five of treatment. "Moving forward, our broad clinical d

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
19 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Enanta's RSV Candidate ...

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint
18 May, 2022 FinancialContent

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise ...

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
18 May, 2022 FinancialContent

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for RSVP, its Phase 2b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints. However, a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment at Day 5 was observed with EDP-938 compared to placebo (p=0.033). Further, EDP-938 demonstrated a favorable safety profile, consistent with that observed in approximately 500 subjects exposed to date. Enanta continues to evaluate EDP-938 in high-risk populations in ongoing and planned clinical studies, including pediatric patients, adult hematopoietic cell transplant recipients, and a high-risk adult population, all of which have the most significant unmet need.

Swelling losses haven't held back gains for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders since they're up 61% over 5 years
12 May, 2022 Yahoo! Finance

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders might be concerned after seeing the share price drop 30% in...

10 Biggest Price Target Changes For Tuesday
10 May, 2022 FinancialContent

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market ...

Enanta Pharmaceuticals (ENTA) Q2 2022 Earnings Call Transcript
10 May, 2022 FinancialContent

ENTA earnings call for the period ending March 31, 2022.

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
09 May, 2022 Yahoo! Finance

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
09 May, 2022 FinancialContent

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2022.

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
05 May, 2022 Yahoo! Finance

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
02 May, 2022 FinancialContent

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
29 Mar, 2022 FinancialContent

Enanta Receives Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

How The Parts Add Up: ESIX Targets $35
24 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the United States Fund Finder & ETF Screener ETF (ESIX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $35.40 per unit.

Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
08 Mar, 2022 FinancialContent

Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
17 Feb, 2022 FinancialContent

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial
16 Feb, 2022 FinancialContent

Enanta Pharmaceuticals Inc(NASDAQ: ENTA) hasdosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL ...

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
16 Feb, 2022 FinancialContent

Enanta Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
11 Feb, 2022 FinancialContent

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference
10 Feb, 2022 FinancialContent

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Where Enanta Pharmaceuticals Stands With Analysts
09 Feb, 2022 FinancialContent

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript
09 Feb, 2022 FinancialContent

ENTA earnings call for the period ending December 31, 2021.

Enanta Pharmaceuticals: Q1 Earnings Insights
08 Feb, 2022 FinancialContent

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what ...

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
08 Feb, 2022 FinancialContent

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
08 Feb, 2022 Yahoo! Finance

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Scheduled For February 8, 2022
08 Feb, 2022 FinancialContent

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on ...

Why Enanta Pharmaceuticals (ENTA) Might Surprise This Earnings Season
07 Feb, 2022 Yahoo! Finance

Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021
01 Feb, 2022 FinancialContent

Enanta to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
13 Jan, 2022 FinancialContent

Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) within the last quarter: ...

10 Biggest Price Target Changes For Thursday
13 Jan, 2022 FinancialContent

RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market ...

Enanta Pharmaceuticals, Inc (ENTA) is a NASDAQ Common Stock listed in , ,

970x250